Related Experiment Video

Updated: Jul 3, 2026

Human Liver Microphysiological System for Assessing Drug-Induced Liver Toxicity In Vitro
11:06

Human Liver Microphysiological System for Assessing Drug-Induced Liver Toxicity In Vitro

Published on: January 31, 2022

Primary hepatocytes as a model to analyze species-specific toxicity and drug metabolism

Gregor Tuschl1, Birthe Lauer, Stefan O Mueller

  • 1Merck KGaA, Merck Serono, Non-Clinical Development, Early and Explanatory Toxicology, Frankfurter Str. 250, 64293 Darmstadt, Germany.

Expert Opinion on Drug Metabolism & Toxicology
|July 16, 2008
PubMed
Abstract

Insights

Early detection of drug-induced liver injury is crucial. Primary hepatocyte cultures effectively identify liver toxicity and species-specific drug effects in preclinical development.

Area of Science:

  • Pharmacology
  • Toxicology
  • Hepatology

Background:

  • Drug-induced liver injury (DILI) is a significant challenge in late-stage pharmaceutical development.
  • DILI often manifests in clinical trials or post-approval due to species-specific metabolic differences and idiosyncratic reactions.
  • Early identification of hepatotoxicity is critical for drug development efficiency and patient safety.

Purpose of the Study:

  • To establish an early detection system for unfavorable drug effects on the liver.
  • To enhance the safety and efficiency of pharmaceutical drug development.
  • To predict potential hepatotoxicity before human trials.

Main Methods:

  • Utilizing primary hepatocyte cultures from diverse species, including humans.
  • Analyzing morphological changes in hepatocytes post-compound treatment.
  • Assessing functional and gene expression alterations in response to drug candidates.

Main Results:

  • Primary hepatocyte cultures demonstrate sensitivity to compound-induced toxicity.
  • The method allows for the evaluation of species-specific responses to drug compounds.
  • Observed alterations in morphology, function, and gene expression indicate potential hepatotoxicity.

Conclusions:

  • Primary hepatocyte cultures are a valuable tool for detecting general liver toxicity.
  • This approach aids in evaluating species-specific drug effects.
  • Hepatocyte cultures offer a promising strategy for early-stage toxicity screening in drug development.

More Related Videos

Robust Generation of Hepatocyte-like Cells from Human Embryonic Stem Cell Populations05:49

Robust Generation of Hepatocyte-like Cells from Human Embryonic Stem Cell Populations

Published on: October 26, 2011

An All-Human Hepatic Culture System for Drug Development Applications07:23

An All-Human Hepatic Culture System for Drug Development Applications

Published on: October 20, 2023

Related Concept Videos

Effect of Hepatic Disease on Pharmacokinetics: Pathophysiologic Assessment and Liver Function Test01:22

Effect of Hepatic Disease on Pharmacokinetics: Pathophysiologic Assessment and Liver Function Test

In clinical practice, the direct measurement of hepatic blood flow to evaluate liver function presents significant challenges due to the intricate and specialized nature of the necessary techniques. Consequently, healthcare professionals often rely on empirical estimates derived from thorough patient examinations and liver function tests to gauge liver health. Among the tools at their disposal, the Child–Pugh and MELD scoring systems stand out for their ability to categorize and assess the...
Physiological Pharmacokinetic Models: Incorporating Hepatic Transporter-Mediated Clearance01:07

Physiological Pharmacokinetic Models: Incorporating Hepatic Transporter-Mediated Clearance

Drug transporters are critical in drug absorption, distribution, and excretion processes. They should be included in physiological-based pharmacokinetic (PBPK) models, which help predict human drug disposition. However, predicting this is challenging during drug development, especially when liver transport is involved. However, with a realistic representation of body transport processes, an accurate model may be possible.
A recent model describes pravastatin's hepatobiliary excretion, mediated...
Effect of Hepatic Disease on Pharmacokinetics: Drug Dosing and Hepatic Blood Flow01:26

Effect of Hepatic Disease on Pharmacokinetics: Drug Dosing and Hepatic Blood Flow

Chronic liver disease significantly impacts drug metabolism due to alterations in hepatic blood flow and enzyme accessibility. This disruption affects the body's pharmacokinetics—the movement and processing of drugs within the system. Key enzymes crucial for metabolizing medications become less accessible, changing how drugs are processed and utilized. Furthermore, liver disease influences the synthesis of plasma proteins, such as albumin and globulins, which play critical roles in drug binding...
Toxicity Testing in Animals01:23

Toxicity Testing in Animals

Toxicity tests in animals are grounded on two main assumptions: first, the effects observed in laboratory animals can be extrapolated to humans, especially when adjusted for body surface area; second, high-dose exposure in animals is essential to identify potential human hazards from lower doses. This is based on the quantal dose-response concept, which faces the challenge of extrapolating results from relatively few test animals to much larger human populations. For example, a 0.01% incidence...
Drug toxicity: Idiosyncratic Reactions01:16

Drug toxicity: Idiosyncratic Reactions

Idiosyncratic drug reactions represent abnormal chemical responses that vary significantly among individuals, ranging from extreme sensitivity to low doses to insensitivity to high doses. These reactions often occur due to the drug's covalent binding with serum proteins, forming a foreign hapten that triggers an immunotoxicological response. The variability in drug reactions has a strong pharmacogenetic foundation, with genetic differences crucial in how individuals metabolize drugs. For...
Effect of Hepatic Disease on Pharmacokinetics: Active Drug, Metabolite and Fraction of Metabolized Drug01:14

Effect of Hepatic Disease on Pharmacokinetics: Active Drug, Metabolite and Fraction of Metabolized Drug

In pharmacotherapy, monitoring drug concentrations is paramount, especially for drugs whose therapeutic effects hinge on both the active compound and its metabolite. Hepatic impairment profoundly influences drug potency by altering liver function. If the drug is more potent than its metabolite, impaired liver function amplifies drug activity due to elevated drug concentration levels. Conversely, if the metabolite holds greater potency, diminished liver function diminishes drug activity by...